$CLOV

OLDAKOWSKI JOSEPH FRANK sold $15K of CLOV

OLDAKOWSKI JOSEPH FRANK (VP OF FINANCE AND CONTROLLER) sold 3,170 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.64 on 2026-09-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · OLDAKOWSKI JOSEPH FRANK
Published Sep 17, 2026, 9:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 9:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLOV
Neutral
high confidence
Mentioned
$CLOV
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVNeutralLow
01

Why it matters

The disclosed sale is routine and unlikely to affect market perception of Clover Health.

02

Market read

A small insider sell with no immediate price impact; primarily of interest to compliance and monitoring teams.

03

What to watch

Potential future dilution from upcoming financing rounds could make the current stake less significant.

Relevance 2/10Novelty 3/10Timing: post‑market 2026‑09‑16 filing

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan indicates pre‑scheduled trades.

Company-level read

Ticker impact

$CLOVNeutralHigh confidence
Context

VP of Finance sold 3,170 shares for $14.7K via a 10b5‑1 plan, reducing his stake to 275,897 shares.

Expected impact

No material price impact expected.

Evidence & confidence

The sale size is small relative to float and disclosed under a pre‑arranged plan, indicating routine portfolio rebalancing rather than loss of confidence.

Market effects

None; the transaction is company‑specific and does not affect the health‑tech sector.

None; Clover Health trades on US exchanges only.

None; the sale is too small to influence broader markets.

Counterpoint

If the insider had insider knowledge of upcoming negative news, the sale could be a warning sign, but the 10b5‑1 plan weakens that argument.

Key entities

  • Clover Health Investments, Corp.

    US‑listed health‑tech firm (ticker CLOV).

  • Joseph Frank Oldakowski

    Vice President of Finance and Controller, insider reporter.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ASTHMed

Astrana Health, Clover Health, Alignment Healthcare, and Novavax Stocks Trade Down, What You Need To Know

Several healthcare stocks fell after bipartisan lawmakers introduced the Protecting Approved Care Act, which aims to reform Medicare Advantage plans. The bill could increase medical loss ratios and administrative burdens for insurers. Astrana Health (ASTH) fell 2.7%, Clover Health (CLOV) 4.8%, Alignment Healthcare (ALHC) 12.6%, and Novavax (NVAX) 3.6%.

$CLOVHigh

Clover Health (CLOV) Gets New ‘Buy’ Call, Higher PT, Climbs 8.5%

Clover Health (CLOV) shares rose 8.53% to $4.71 after Deutsche Bank initiated coverage with a 'buy' rating and $6 price target, citing growth potential in Medicare Advantage and its technology platform. The company reported Q2 net income of $28M, up from a $10.6M loss YoY, with revenues increasing 55.6% to $743.2M. Medicare Advantage membership grew 48% to 157,309. Clover raised its net income and revenue guidance for the year. Hedge fund holdings in CLOV increased fourfold to $79.06M.

$CLOVMed

Clover Health (CLOV) Shares Skyrocket, What You Need To Know

Clover Health (CLOV) shares rose 8.5% after Deutsche Bank initiated coverage with a Buy rating and $6.00 price target, citing growth in Medicare Advantage, its Clover Assistant platform, and its risk model. The stock has seen high volatility, with a 24.2% drop last year due to disappointing earnings and lowered guidance. CLOV is up 96.9% YTD but trades 12.3% below its 52-week high.

$PGNYHighAI 8/10

Spotting Winners: Progyny (NASDAQ:PGNY) And Health Insurance Providers Stocks In Q2

Progyny (PGNY) and other health insurers reported Q2 earnings, with revenues beating estimates by 2.8% but guidance below expectations. PGNY's revenue grew 5.3% YoY, missing EBITDA guidance. CVS Health (CVS) reported 7.3% YoY revenue growth, beating estimates. Molina Healthcare (MOH) saw a 4.8% YoY revenue decline. Alignment Healthcare (ALHC) grew 31.6% YoY, while Clover Health (CLOV) saw 55.6% YoY growth. Stocks have declined since earnings, except CLOV, which rose 4.3%.

$CLOVHighAI 8/10

Clover Health (CLOV) Turns Profitable As Medicare Membership Explodes

Clover Health (CLOV) reported Q2 2026 net income of $28M, reversing a $10.6M loss from the prior year. Medicare Advantage membership grew 48% YoY to 157,309. Revenue rose 55.6% to $743.2M, and adjusted EBITDA more than doubled. The company raised its full-year guidance, including adjusted EBITDA to $70M-$85M and GAAP net income to $20M-$35M. Cash and investments increased 13.8% YoY to $443.0M.